[The treatment of metastasizing breast carcinoma using antiestrogens].

Abstract

Results of adjuvant hormone therapy with Tamoxifen, an antioestrogenic substance, have been discussed. 82 patients in 2 groups who were diagnosed with metastatic mammary carcinoma received Tamoxifen (ICI) and Tamoxifen (Ebewe) orally in a dosage of 20 to 40 mg/day. 43% of the patients in group A (Tamoxifen, ICI) experienced complete or partial remission of the metastases. In group B (Tamoxifen, Ebewe), this result was achieved in 54% of cases. The better results were due to the fact that the disease was not so advanced in the group B patients and they were also longer in the menopause. Thus in terms of efficacy, the preparations are identical. Severe side effects due to the therapy were not observed.

• Authors: T Pienkowski, A Palucka-Bartoszewicz, F Pienkowska, J Zborzil, J Schneider
• Journal: Wiener medizinische Wochenschrift (1946) (Wien Med Wochenschr) Vol. 141 Issue 13 Pg. 294, 297-300 ( 1991) ISSN: 0043-5341 [Print] Austria
• Vernacular Title: Behandlung des metastasierenden Mamma-karzinoms unter Anwendung von Antiöstrogenen.
• PMID: 1926878 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Tamoxifen

Topics

• Adult
• Age Factors
• Aged
• Aged, 80 and over
• Breast Neoplasms (drug therapy, pathology)
• Female
• Humans
• Middle Aged
• Remission Induction
• Tamoxifen (adverse effects, therapeutic use)